文献速递复苏、休克与脓毒症心脑血管急症

左西孟旦对缺血性心脏骤停模型生存与心功能的影响:猪盲法随机安慰剂对照研究

The effect of levosimendan on survival and cardiac performance in an ischemic cardiac arrest model - A blinded randomized placebo-controlled study in swine.
PubMed 文献 · Resuscitation · 2020-03-28
一句话结论猪缺血性心脏骤停模型中,心肺复苏时及复苏后24小时给予左西孟旦改善了生存与心输出量恢复,但心肌瘢痕面积无差异。

该研究为盲法随机安慰剂对照猪实验,24头麻醉猪经实验诱导急性心肌梗死与心室颤动后接受心肺复苏。复苏开始时给予左西孟旦负荷量12 μg kg-1或安慰剂,自主循环恢复后持续输注0.2 μg kg-1 min-1共24小时。左西孟旦组全部12头恢复自主循环,安慰剂组8/12(P=0.09);左西孟旦组方案生存率更高(P=0.02),估计死亡风险较安慰剂降低88%(HR 0.12,95%CI 0.01-0.96,P=0.046);重症监护第一小时心输出量恢复快40%(差值0.13 L min-1,95%CI 0.01-0.26,P=0.04)。MRI显示心肌瘢痕面积或心肌危险区无差异。

要点

  • 猪缺血性心脏骤停模型中,复苏时给予左西孟旦负荷量12 μg kg-1、自主循环恢复后输注0.2 μg kg-1 min-1共24小时,方案生存率高于安慰剂(P=0.02),估计死亡风险降低88%(HR 0.12,95%CI 0.01-0.96,P=0.046)。
  • 左西孟旦组12/12头恢复自主循环,安慰剂组8/12头恢复(P=0.09),差异未达统计学显著。
  • 重症监护第一小时左西孟旦组心输出量恢复快40%(差值0.13 L min-1,95%CI 0.01-0.26,P=0.04);安慰剂组需要更高正性肌力支持,掩盖了左西孟旦组更大的心输出量恢复(58%)。
  • MRI显示两组心肌瘢痕面积与心肌危险区无差异。

适用人群与场景

  • 麻醉猪经实验诱导急性心肌梗死与心室颤动后接受心肺复苏的缺血性心脏骤停模型。

处置流程与药物剂量

  • 心肺复苏开始时给予左西孟旦负荷量12 μg kg-1或安慰剂。
  • 自主循环恢复后给予左西孟旦0.2 μg kg-1 min-1持续输注24小时。

研究设计与关键结果

  • 研究类型:盲法、安慰剂对照随机猪实验,样本量24头。
  • 干预与对照:复苏开始时左西孟旦负荷量12 μg kg-1或安慰剂,自主循环恢复后左西孟旦0.2 μg kg-1 min-1输注24小时。
  • 自主循环恢复:左西孟旦组12/12头 vs 安慰剂组8/12头(P=0.09)。
  • 方案生存率:左西孟旦组高于安慰剂组(P=0.02),估计死亡风险较安慰剂降低88%(HR 0.12,95%CI 0.01-0.96,P=0.046)。
  • 心输出量:重症监护第一小时左西孟旦组恢复快40%(差值0.13 L min-1,95%CI 0.01-0.26,P=0.04);安慰剂组需要更高正性肌力支持,掩盖了左西孟旦组更大的心输出量恢复(58%)。
  • MRI:两组心肌瘢痕面积与心肌危险区无差异。

证据类型、等级与局限

  • 证据类型:盲法随机安慰剂对照猪实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该猪缺血性心脏骤停模型结果提示,复苏时及复苏后24小时给予左西孟旦可能改善生存与心输出量恢复,但心肌瘢痕面积无差异;尚不能直接转化为临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Survival after out-of-hospital cardiac arrest remains poor. Levosimendan could be a new intervention in this setting. Therefore, we conducted a blinded, placebo controlled randomized study investigating the effects of levosimendan on survival and cardiac performance in an ischemic cardiac arrest model in swine.

METHODS: Twenty-four anesthetised swines underwent experimentally-induced acute myocardial infarction and ventricular fibrillation. At the start of CPR, a bolus dose of levosimendan (12 μg kg-1) or placebo was given followed by a 24-h infusion (0.2 μg kg-1 min-1) after return of spontaneously circulation. Animals were evaluated by risk of death, post-resuscitation hemodynamics and infarction size by magnetic resonance imaging (MRI) up to 32 h post arrest.

RESULTS: Spontaneous circulation was restored in all (12/12) animals in the levosimendan group compared to two thirds (8/12) in the placebo group (P = 0.09). Protocol survival was higher for the levosimendan group (P = 0.02) with an estimated 88% lower risk of death compared to placebo (hazard ratio [95% confidence interval] 0.12 [0.01-0.96], P = 0.046). Cardiac output (CO) recovered 40% faster during the first hour of the intensive care period for the levosimendan group (difference 0.13 [0.01-0.26] L min-1P = 0.04). The placebo group required higher inotropic support during the intensive care period which masked an even bigger recovery in CO in the levosimendan group (58%). The MRI showed no difference in myocardial scar size or in myocardial area at risk.

CONCLUSIONS: Levosimendan given intra-arrest and during the first 24-h of post-resuscitation care improved survival and cardiac performance in this ischemic cardiac arrest model. Institutional Protocol Number; KERIC 5.2.18-14933.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Rysz S, Lundberg J, Nordberg P, et al. The effect of levosimendan on survival and cardiac performance in an ischemic cardiac arrest model - A blinded randomized placebo-controlled study in swine. Resuscitation. 2020. PMID: 32234367. doi:10.1016/j.resuscitation.2020.02.032

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。